Highest reported mean weight change at 80 weeks for the 12 mg group using the efficacy estimand.
Traducción automática para su comodidad. Para decisiones médicas,
confirme los detalles con nuestro equipo bilingüe.
Positive Phase 3 topline data · Not FDA-approved
Retatrutide: Available through certified compounding Rx only
Retatrutide is an investigational triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. Multiple Phase 3 studies have reported positive topline results, but FDA has not approved retatrutide for any condition.
Clinical Snapshot
What patients should know first
Retatrutide has generated substantial interest because of its Phase 3 weight-loss results, but sponsor-reported study findings and regulatory approval are not the same thing.
Commonly discussed for
Potential next-generation weight treatment, sometimes called
“triple-G” because it activates GIP, GLP-1 and glucagon
receptors.
TRIUMPH-1
Lilly reported mean weight changes at 80 weeks of −19.0%,
−25.9% and −28.3% for 4, 9 and 12 mg, versus −2.2% with
placebo, using an efficacy estimand. These are sponsor-reported
topline data pending full peer-reviewed publication and FDA
review.
TRIUMPH-2 & -3
On July 23, Lilly reported up to −20.8% mean weight change in
adults with obesity or overweight and type 2 diabetes and up
to −22.6% in adults with severe obesity and established
cardiovascular disease. The cardiovascular event analyses
were imprecise and did not establish cardiovascular benefit.
Approval boundary
There is no FDA-approved retatrutide product as of July 31,
2026. FDA says retatrutide cannot be used in compounding under
federal law and warns against products sold directly to
consumers as compounded or “research” retatrutide.
What may happen next
Lilly states that it plans to submit a Biologics License
Application in Q1 2027. A planned submission is not a filing,
review completion, approval date or guarantee.
Safety context
Gastrointestinal events, dysesthesia and treatment
discontinuations increased in some dose groups. Long-term
benefit-risk assessment and manufacturing review remain
incomplete until FDA reviews a submitted application.
Phase 3 Results
What the latest topline data show
These figures are sponsor-reported study results. They should not be read as guaranteed individual outcomes or FDA-reviewed approval evidence.
Up to this mean weight change was reported in adults with obesity or overweight and type 2 diabetes.
Up to this mean weight change was reported in adults with severe obesity and established cardiovascular disease.
Trial averages are not a promise of an individual result. Cardiovascular event analyses described in the sponsor-reported TRIUMPH-2 and TRIUMPH-3 results were imprecise and did not establish cardiovascular benefit.
Development Tracker
Where retatrutide stands today
This visual represents regulatory progression only. Bar length is not a probability of approval, clinical score or comparison with another medication.
Phase 2
Published
Phase 3
Topline Results
FDA Application
Planned Q1 2027
FDA Approval
Not Approved
Status checked July 31, 2026. Bar length is a design aid for the development process and should not be interpreted as a forecast.
Investigational does not mean available.
Positive clinical trial results do not create an FDA-approved product. As of the source-review date, retatrutide remains an investigational drug and products advertised directly to consumers as compounded or research retatrutide should not be confused with the investigational product studied in Lilly's clinical development program.
Interpretation
Do not confuse a molecule with a verified medication
The name of an active ingredient does not verify the product in a vial. FDA approval, when it exists, applies to a specific product and indication. A compounded version is not FDA-approved, and a research-labeled product is not approved for human use.
Clinical supervision should include diagnosis, contraindication and interaction review, realistic outcome discussion, a valid prescription, traceable sourcing and follow-up. It cannot make an anonymous or counterfeit product safe.
Primary Sources
Verify the evidence
Regulatory status and clinical-trial claims should be checked against primary government, trial-registry and published research sources whenever possible.
Evidence Before Treatment
This guide is educational and cannot determine whether any medication or investigational therapy is appropriate for you. Retatrutide is not FDA-approved as of the source-review date. Regulatory status, trial findings and product availability can change; verify current information and speak with an appropriately licensed clinician about approved treatment options.